Figure 2.
HBV was detected in DLBCL in situ. Anti-HBc, -HBs, and -HBx antibodies were used to detect the HBV antigen in several lymphoma tissue sections by immunohistochemistry. (A) Lymph node tissue from a DLBCL patient with HBV antigen-negative serum; (B) Patient with HBsAg-positive serum (> 250 IU/mL) and HBV DNA-positive serum (5.2×103 IU/mL); (C) IRS of immunohistochemistry from five serum HBV antigen-negative and ten HBV antigen-positive patients. The scores are expressed as the mean ± standard deviation and statistics were carried out by one-way ANOVA, ***P<0.001; (D) DNA was extracted from DLBCL paraffin tissue, and HBV DNA was detected by PCR using total-HBV or 3.5kb-HBV DNA primers. DNA in lanes 1 to 3 were extracted from DLBCL tissues of HBV-positive serum and lane 4 was from that of HBV-negative serum.